Corcept Therapeutics (CORT) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 --0%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.09 better than the analyst estimate of $0.23. Revenue for the quarter came in at $163.8 million versus the consensus estimate of $155.22 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
- Intellia Therapeutics (NTLA) Misses Q3 EPS by 11c
- Maris-Tech forecasts 2026 gross revenue above $5M
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
